ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1916

Clinical Features of the Patients with NLRP1 Gene Variants and a Systemic Autoinflammatory Phenotype

Shirkhan Amikishiyev1, Tuğba Kalaycı2, Rabia Deniz3, Yasemin Yalçınkaya4, Bahar Artim-Esen1, Murat Inanc1, Ayla Sahin2, Sema Sırma Ekmekci5, Neslihan Abacı5, Sukru Ozturk2, Sukru Palanduz2 and Ahmet Gul1, 1Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 2Department of Genetics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 3Division of Rheumatology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey, 4Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 5Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Genetics, Istanbul, Turkey

Meeting: ACR Convergence 2023

Keywords: Autoinflammatory diseases, genetics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1913–1944) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Although NLRP1 was the first identified member of the NOD-like receptors family, its role as a sensor of pathogen- or damage-associated signals and its connection with systemic autoinflammatory disorders (SAIDs) have not been clarified yet. Missense or non-sense variations of the NLRP1 gene have already been associated with some clinical phenotypes including dyskeratosis, arthritis, recurrent fever, chronic infections, recurrent acute phase response, recurrent respiratory papillomatosis, keratosis pilaris, palmoplantar wart-like hyperkeratotic papules, atrophoderma vermiculata, and familial keratosis lichenoides chronica. Some polymorphisms have also been associated with autoimmune disorders. We herein report the clinical findings of 5 patients with NLRP1 variants.

Methods: The study group included the patients who were referred to our center with a potential diagnosis of SAID and screened for variants of 22 autoinflammatory genes. Those patients with NLRP3 variants were identified, and their clinical and laboratory findings were evaluated.

Results: A total of 146 cases with potential diagnosis of SAID were included, and their genetic analysis results were evaluated. NLRP1 variants were identified in 5 (3.4 %) cases. All of the NLRP1 gene variants were classified as variant of uncertain significance (VUS). All but one patients had additional variants in other autoinflammatory genes (Table 1). The most common clinical finding was recurrent urticaria (n=4). Case 1 had NLRP3-AID-like clinical phenotype in addition to Crohn’s disease with sacroiliitis. Case 2 had scleritis attacks and had a combination of two gene variants. Case 3 had Behçet’s disease-like phenotype with oral aphthous stomatitis, genital ulcers, and cerebrovascular event with VUS in both NLRC4 and NLRP1 genes. Case 4 had a TRAPS-like phenotype with serositis and periorbital edema with NLRP1 VUS and a pathogenic MEFV variant. Case 5 had an FMF-like phenotype with VUS in the NLRP1 VUS and a pathogenic variant in the MEFV genes along with five different gene variants. None of the patients had a family history for a phenotype compatible with SAIDs.

Conclusion: NLRP1-associated SAID has been emerging as a new entity, and the phenotypic features of the reported patients varied significantly according to the positions of the variants within the different domains of the gene (Figure 1). We herein report 4 patients with recurrent urticaria as the most common clinical feature in association with 3 different VUS in the NLRP1 gene, and none of the accompanying genetic variants have not been related to urticaria below. The NLRP1 gene p.Val939Met variant is a relatively common variant (allele frequency 0.01), but relatively frequent observation of this variant in the current patient group may suggest that it may have a functional role very similar to the relatively common variant of p.Gln703Lys in the NLRP3 gene. One of the remaining two variants (p.Val1235Ile) was not reported before, and the other one (p.Cys904Ter) was expected to have a pathogenic role due to early termination of the protein (Figure 1). Collection of more cases would help clarify the spectrum of clinical findings of the patients with NLRP1-AID.

Supporting image 1

Table 1: Genotype and phenotypes of patients with NLRP1 variants. *: Pathogenic and likely pathogenic, ⴕ: VUS

Supporting image 2

Figure 1: NLRP1 variants and phenotypic features of the reported patients (above the line) and our cases (below the line).


Disclosures: S. Amikishiyev: None; T. Kalaycı: None; R. Deniz: None; Y. Yalçınkaya: None; B. Artim-Esen: None; M. Inanc: None; A. Sahin: None; S. Ekmekci: None; N. Abacı: None; S. Ozturk: None; S. Palanduz: None; A. Gul: None.

To cite this abstract in AMA style:

Amikishiyev S, Kalaycı T, Deniz R, Yalçınkaya Y, Artim-Esen B, Inanc M, Sahin A, Ekmekci S, Abacı N, Ozturk S, Palanduz S, Gul A. Clinical Features of the Patients with NLRP1 Gene Variants and a Systemic Autoinflammatory Phenotype [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/clinical-features-of-the-patients-with-nlrp1-gene-variants-and-a-systemic-autoinflammatory-phenotype/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-features-of-the-patients-with-nlrp1-gene-variants-and-a-systemic-autoinflammatory-phenotype/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology